You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 22, 2024

Angiotensin ii acetate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for angiotensin ii acetate and what is the scope of patent protection?

Angiotensin ii acetate is the generic ingredient in one branded drug marketed by La Jolla Pharma and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Angiotensin ii acetate has forty-four patent family members in twenty-three countries.

One supplier is listed for this compound.

Summary for angiotensin ii acetate
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for angiotensin ii acetate
Generic Entry Date for angiotensin ii acetate*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for angiotensin ii acetate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Kasr El Aini HospitalN/A
National Heart, Lung, and Blood Institute (NHLBI)Phase 2
American Lung AssociationPhase 2

See all angiotensin ii acetate clinical trials

Pharmacology for angiotensin ii acetate
Drug ClassVasoconstrictor
Physiological EffectVasoconstriction
Medical Subject Heading (MeSH) Categories for angiotensin ii acetate
Paragraph IV (Patent) Challenges for ANGIOTENSIN II ACETATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
GIAPREZA Injection angiotensin ii acetate 2.5 mg/mL 209360 1 2021-12-21

US Patents and Regulatory Information for angiotensin ii acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-002 Dec 21, 2017 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-001 Dec 21, 2017 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-003 Dec 23, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-002 Dec 21, 2017 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-003 Dec 23, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-003 Dec 23, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for angiotensin ii acetate

Country Patent Number Title Estimated Expiration
South Korea 20180108639 안지오텐신 II를 투여하는 방법 ⤷  Try a Trial
Japan 6824739 ⤷  Try a Trial
China 111920939 血管紧张素II单独或以组合方式用于治疗低血压 (Angiotensin ll alone or in combination for the treatment of hypotension) ⤷  Try a Trial
Eurasian Patent Organization 201691258 АНГИОТЕНЗИН II САМОСТОЯТЕЛЬНО ИЛИ В КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ ГИПОТЕНЗИИ ⤷  Try a Trial
Taiwan 201733610 Methods for administering angiotensin II ⤷  Try a Trial
Israel 246162 אנגיוטנסין ii, לבד או בשילוב, לטיפול בלחץ דם נמוך (Angiotensin ii alone or in combination for the treatment of hypotension) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.